title: Effect of aspartate and glutamate on nociception, catalepsy and core temperature in rats.
abstract: Effects of excitatory aminoacids (EAAs) aspartate (ASP) and glutamate (GLU) in a low (50 ng, i.c.) and high dose (20 micrograms, i.c.), were studied on nociception, catalepsy and rectal temperature in albino rats. Both ASP and GLU altered the tail flick reaction time to thermal stimulation in a dose dependent manner, increasing it with low doses and reduced with high doses. Naloxone (10 micrograms, ic) antagonized the anti-nociceptive effect of EAAs while ketamine (10 micrograms, ic)-a NMDA receptor antagonist antagonized the hyperalgesic effect. These EAAs also antagonized catalepsy induced by haloperidol, chlorpromazine, trifluoperazine and morphine. Both ASP and GLU produced a hyperthermic response in all animals, including those in which hypothermia was induced by reserpine. These EAAs produced a comparable central modulatory effects on nociception, catalepsy and core temperature.
authors.affiliation: Department of Pharmacology, Pt. B.D. Sharma Postgraduate Institute of Medical Sciences, Rohtak.
authors.forename: J
authors.initials: J
authors.lastname: Singh
authors.forename: M C
authors.initials: MC
authors.lastname: Gupta
mesh_terms: D018759:Adrenergic Uptake Inhibitors / Q000633:toxicity; D000698:Analgesia; D000701:Analgesics, Opioid / Q000008:administration & dosage / Q000633:toxicity; D000818:Animals; D001224:Aspartic Acid / Q000008:administration & dosage / Q000494:pharmacology* / Q000627:therapeutic use; D001831:Body Temperature / Q000187:drug effects* / Q000502:physiology; D002375:Catalepsy / Q000188:drug therapy*; D002746:Chlorpromazine / Q000008:administration & dosage / Q000494:pharmacology; D018492:Dopamine Antagonists / Q000008:administration & dosage / Q000633:toxicity; D004305:Dose-Response Relationship, Drug; D018691:Excitatory Amino Acid Antagonists / Q000633:toxicity; D005334:Fever / Q000139:chemically induced; D018698:Glutamic Acid / Q000008:administration & dosage / Q000494:pharmacology* / Q000627:therapeutic use; D006220:Haloperidol / Q000008:administration & dosage / Q000633:toxicity; D007035:Hypothermia / Q000139:chemically induced; D007279:Injections, Subcutaneous; D007649:Ketamine / Q000494:pharmacology; D008297:Male; D009020:Morphine / Q000008:administration & dosage / Q000633:toxicity; D009270:Naloxone / Q000008:administration & dosage / Q000494:pharmacology; D009292:Narcotic Antagonists / Q000008:administration & dosage / Q000494:pharmacology; D009619:Nociceptors / Q000187:drug effects*; D051381:Rats; D012110:Reserpine / Q000633:toxicity; D014268:Trifluoperazine / Q000008:administration & dosage / Q000494:pharmacology
chemical_list: D018759:Adrenergic Uptake Inhibitors; D000701:Analgesics, Opioid; D018492:Dopamine Antagonists; D018691:Excitatory Amino Acid Antagonists; D009292:Narcotic Antagonists; D014268:Trifluoperazine; D001224:Aspartic Acid; D009270:Naloxone; D018698:Glutamic Acid; D007649:Ketamine; D009020:Morphine; D012110:Reserpine; D006220:Haloperidol; D002746:Chlorpromazine